CSL Limited (ASX:CSL)
Australia
· Delayed Price · Currency is AUD 234.34
-5.64 (-2.35%)
Jun 27, 2025, 4:11 PM AEST
CSL Limited Employees
CSL Limited had 32,698 employees as of June 30, 2024. The number of employees increased by 633 or 1.97% compared to the previous year.
Employees
32,698
Change (1Y)
633
Growth (1Y)
1.97%
Revenue / Employee
752.65K AUD
Profits / Employee
135.80K AUD
Market Cap
117.16B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cochlear | 5,097 |
| Sonic Healthcare | 42,000 |
| Ramsay Health Care | 90,000 |
| Telix Pharmaceuticals | 234 |
| Ansell | 15,000 |
| Regis Healthcare | 11,000 |
| Mesoblast | 73 |
| Neuren Pharmaceuticals | 8 |
CSL Limited News
- 11 days ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 5 weeks ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
- 2 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire
- 3 months ago - CSL Limited: Divergent Outlook For Its 2 Key Businesses - Seeking Alpha
- 4 months ago - CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 4 months ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 4 months ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - Business Wire
- 4 months ago - European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire